XML 80 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Product Sales (Tables)
 9 Months Ended
Sep. 30, 2019
Revenues [Abstract]  
Schedule of product sales
Net product sales consist of the following:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Net Product Sales in the United States
 
2019
 
2018
 
2019
 
2018
EYLEA®
 
$
1,187.7

 
$
1,021.8

 
$
3,422.1

 
$
2,997.8

Libtayo®
 
47.6

 
—

 
115.2

 
—

ARCALYST®
 
3.0

 
3.7

 
10.7

 
12.0

 
 
$
1,238.3

 
$
1,025.5

 
$
3,548.0

 
$
3,009.8


Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which were previously terminated):
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Bayer EYLEA Collaboration Revenue
 
2019
 
2018
 
2019
 
2018
Regeneron's net profit in connection with commercialization of EYLEA outside the United States
 
$
275.0

 
$
243.2

 
$
793.3

 
$
721.5

Reimbursement of Regeneron EYLEA development expenses
 
5.0

 
1.7

 
15.6

 
8.8

Other
 
22.8

 
20.7

 
59.1

 
45.4

 
 
$
302.8

 
$
265.6

 
$
868.0

 
$
775.7


The collaboration revenue we earned from Sanofi is detailed below:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Sanofi Collaboration Revenue
 
2019
 
2018
 
2019
 
2018
Antibody:
 
 
 
 
 
 
 
 
Reimbursement of Regeneron research and development expenses
 
$
60.2

 
$
76.2

 
$
216.5

 
$
201.0

Reimbursement of Regeneron commercialization-related expenses
 
111.6

 
103.7

 
349.3

 
292.8

Reimbursement for Regeneron's manufacturing of commercial supplies
 
78.5

 
40.3

 
133.3

 
94.4

Regeneron's share of profits (losses) in connection with commercialization of antibodies
 
94.2

 
(38.9
)
 
105.2

 
(182.6
)
Other
 
4.8

 
(7.2
)
 
(0.6
)
 
(12.3
)
Total Antibody
 
349.3

 
174.1

 
803.7

 
393.3

Immuno-oncology:
 
 
 
 
 
 
 
 
Reimbursement of Regeneron research and development expenses
 
38.0

 
74.8

 
120.9

 
225.7

Reimbursement of Regeneron commercialization-related expenses
 
3.0

 
3.2

 
7.0

 
6.5

Amounts recognized in connection with up-front payments received
 
18.5

 
7.9

 
73.8

 
65.2

Other
 
(4.6
)
 
(3.7
)
 
(5.7
)
 
(7.2
)
Total Immuno-oncology
 
54.9

 
82.2

 
196.0

 
290.2

 
 
$
404.2

 
$
256.3

 
$
999.7

 
$
683.5
Schedules of Concentration of Risk, by Risk Factor
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the three and nine months ended September 30, 2019 and 2018. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2019
 
2018
 
2019
 
2018
Besse Medical, a subsidiary of AmerisourceBergen Corporation
 
57
%
 
57
%
 
57
%
 
56
%
McKesson Corporation
 
34
%
 
36
%
 
33
%
 
37
%
Sales Related Deductions Activity
The following table summarizes the provisions, and credits/payments, for sales-related deductions during the nine months ended September 30, 2019 and 2018.
 
Rebates, Chargebacks, and Discounts
 
Distribution-Related Fees
 
Other Sales-Related Deductions
 
Total
Balance as of December 31, 2018
$
41.1

 
$
42.0

 
$
8.3

 
$
91.4

Provisions
301.0

 
177.3

 
46.0

 
524.3

Credits/payments
(265.8
)
 
(172.5
)
 
(40.7
)
 
(479.0
)
Balance as of September 30, 2019
$
76.3

 
$
46.8

 
$
13.6

 
$
136.7

 
 
 
 
 
 
 
 
Balance as of December 31, 2017
$
29.9

 
$
34.1

 
$
21.3

 
$
85.3

Provisions
159.1

 
155.5

 
29.7

 
344.3

Credits/payments
(145.9
)
 
(150.9
)
 
(35.7
)
 
(332.5
)
Balance as of September 30, 2018
$
43.1

 
$
38.7

 
$
15.3

 
$
97.1